TOKYO -- Japan's Takeda Pharmaceutical has decided to sell its nonprescription drugs business, including vitamin drug Alinamin, to major U.S. private equity firm Blackstone Group for about 250 billion yen ($2.37 billion)
The company intends to reduce debt swollen by Takeda's acquisition of Shire, the U.K. biotech company, and concentrate its management resources on developing prescription drugs, especially cancer treatments.
